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Abstract
Background: The use of combined positron emission tomography/computerised tomography
(PET/CT) scanners in oncology has been shown to improve the staging of tumours and the
detection of relapses. However, mis-registration errors are increasingly recognised to be a
common pitfall of PET/CT studies.
Case Presentation: We report a patient with a germ cell tumour of the testis, who underwent
a PET/CT scan to detect the site of relapse with a view to surgical removal. However, the PET/CT
scan mislocalised the tumour site to be within the T2 vertebral body. A subsequent endoscopic
ultrasound scan however showed the tumour to be anterior to the vertebral body, which was
confirmed at surgery.
Conclusion: In this report, we highlight the artefactual mislocalisation errors which may occur
with PET/CT imaging, and the need to review and verify these scans.
Background
Positron emission tomography (PET) scanning using 2-
18F-fluoro-deoxy-D-glucose (18FDG) uptake has been in
clinical use for over a decade [1,2]. The advantage of PET
scanning is that it provides functional information of
lesions detected, and can help distinguish between malig-
nant and non-malignant tissues. However, PET scanning
has poor spatial resolution in terms of localising lesions.
In contrast, computerised tomography (CT) scanning give
good anatomical, but not functional information. Since
2000, purpose-built combined positron emission tomog-
raphy/computerised tomography (PET/CT) scanners have
been in use which overcome the respective shortcomings
of PET and CT scans [3,4]. The use of PET/CT scans there-
fore holds much promise in the advancement of tumour
localisation and management. Nevertheless, several pit-
falls remain [5]. Of these, the biggest problem is that of
accurate image alignment. This case report illustrates an
example of mislocation of a tumour in a patient with
germ cell tumour (GCT) by PET/CT, and the subsequent
potential clinical impact which results.
Case presentation
A 38-year old man presented in 1988 with a left testicular
mass which was removed and found to be a non-semino-
matous GCT. Staging investigations revealed spread to the
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platin and etoposide (BEP) chemotherapy was initially
given [6], followed by retroperitoneal lymph node dissec-
tion (RPLND) for residual disease. In 1993, his alpha-
fetoprotein (AFP) level began to rise. A radiolabelled anti-
AFP-antibody scan suggested active disease in the right
para-aortic region corresponding to a node near the right
renal vein on CT. This was subsequently resected. Post-
operatively, the AFP initially fell but then increased and
the patient received six cycles of cisplatin, vincristine,
methotrexate, bleomycin alternating with actinomycin D,
cyclophosphomide and etoposide (POMB/ACE) chemo-
therapy [7]. In 1995, the patient had a further relapse with
an AFP rise, and a CT scan showed recurrence in the abdo-
men. Following further tumour resection the patient
underwent high dose chemotherapy (with carboplatin,
cyclophosphomide and etoposide) with autologous stem
cell rescue. In 1997, the patient's AFP level increased
again. Serial CT and 18-fluoro-deoxyglucose-positron
emission tomography (18FDG-PET) did not initially
reveal any new suspicious lesions. However, when the
AFP rose to 2494 ng/ml in 2001, an 18FDG-PET scan dem-
onstrated a lesion in the left superior mediastinum which
matched a 1.4 cm lymph node on CT. This was resected,
and histology showed active yolk sac tumour involving
the excision margins of the lymph node. Consequently in
May 2001 he received four cycles of gemcitabine, carbopl-
atin and paclitaxel followed by a second high dose chem-
otherapy procedure modified to include paclitaxel
(carboplatin, cyclophophamide, etoposide and paclit-
axel) [8].
In January 2004, the AFP level began to rise again. Exten-
sive investigations including a CT of the chest, abdomen
and pelvis, 18FDG-PET scan, magnetic resonance imaging
(MRI) of the brain, microbubble ultrasound of the liver,
and ultrasound of the remaining testis did not reveal any
sites of relapse. Eventually, when the AFP measured 1531
ng/ml in Sep 2004, a repeat 18FDG-PET scan showed an
area of increased uptake in the posterior aspect of the
superior mediastinum just anterior to the vertebral bodies
of T1/2 (Figure 1A and 1B). However, a repeat contrast-
enhanced CT scan and MRI again showed no obvious
defined lesion could be identified in this area, although
there was soft tissue changes related to the previous sur-
gery in the area (Figure 1C and 1D). The MRI scan, in par-
ticular, did not show any abnormal marrow signals. To
further delineate the lesion, the patient underwent a PET/
CT scan. This indicated that the lesion lay in the anterior
part of the vertebral body of T2 (Figure 1E and 1F).
Because of the discrepancy between the PET/CT and the
initial PET scan, he then underwent a trans-oesophageal
endoscopic ultrasound. This showed a 1.3 cm lesion pos-
terior to the oesophagus and anterior to the vertebrae at
approximately T1/2 (Figure 1G). At surgery in November
2004, a retro-oesophageal pre-vertebral tumour was
found (1.9 × 1.3 × 0.4 cm) which was resected. Histologi-
cal examination with immunohistochemical staining was
consistent with relapsed GCT composed of yolk sac ele-
ments (Figure 2A and 2B). Following surgery, the patient
made a good recovery and his AFP normalised in January
2005 (Figure 2C). He remains well with normal markers
on close follow-up.
Conclusion
The case presented here illustrates several learning points.
Firstly, tumour markers surveillance remains a central part
of the early detection system for identifying patients with
relapsing GCTs. Indeed, a rising AFP preceded detection of
the site of recurrence by 5 years and by 10 months in the
2001 and 2004 relapses, respectively. Secondly, if all other
imaging is negative, 18FDG-PET scanning can actually be
the first imaging modality to pick up the site of relapse, as
18FDG-PET scanning can be superior in terms of sensitiv-
ity and specificity to CT in detecting sites of cancer [9,10].
Thirdly, the PET/CT scan misplaced the lesion within the
body of T2. An endoscopic ultrasound resolved the issue
confirming the location as just posterior to the oesopha-
gus and anterior to the vertebral body. In the absence of
the latter information, the patient would have undergone
much more extensive surgery including resection of the
body of T2.
So why did the PET/CT mislocate the lesion? The most
likely possibility is misregistration of the CT and PET
images. In particular, there may be movement artefact due
to respiration effects, which is increasingly recognised [5].
CT acquires imaging data rapidly within one breath-hold,
whilst PET takes many minutes to accumulate a compos-
ite image during which time the patient is breathing. Con-
sequently, peripheral lung lesions maybe mislocated by
15 mm on PET when compared to CT [11]. In our patient,
misregistration due to breathing could have occurred, but
given the central location of the lesion (that is, not in the
lung periphery) this seems less likely. Furthermore, recent
PET/CT scans use respiration-averaged CT to match PET
images or respiratory gating of the PET acquisition to
improve on misregistration issues [12]. This is further
improved by more detector rows in the scanner [13].
Since the PET and CT scans are performed consecutively,
any patient movement between the two scans will poten-
tially also lead to misregistration. Therefore, the isolated
PET and CT images from the PET/CT scan in our patient
were reviewed by the reporters (who are qualified in both
radiology and nuclear medicine) as well as in our multi-
disciplinary meetings with radiology input. The isolated
PET images from the PET/CT was equivocal for whether
the lesion was in the vertebral body or anterior to it (Fig-
ure 1H), while the CT scan (which was without contrast)
was not able to localise the tumour. Although there was
no obvious misalignment of the skin surface or other ana-
tomical markers between the two scans, it was most likely
that a minimal degree of patient movement between thePage 2 of 4
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A: Haematoxylin and eosin stained section of the tumour resected fr m the mediastinal of the patient (100× agnifica-tion)Figur  2
A: Haematoxylin and eosin stained section of the tumour 
resected from the mediastinal of the patient (100× magnifica-
tion). The tumour nodule showed evidence of organoid 
arrangement. B: Section of the resected tumour showing 
tumour cells expressing AFP, as detected by immunohisto-
chemistry (600× magnification). C: Graph of the AFP marker 
profile from 1993 to 2005 showing the history for relapses 
and treatments received by the patient.
A & B: Axial and sagital view of 18FDG-PET scan of the patient showing region of 18FDG uptake anterior to the ver-tebral bodyFigure 1
A & B: Axial and sagital view of 18FDG-PET scan of the 
patient showing region of 18FDG uptake anterior to the ver-
tebral body. C: CT scan of the positive region identified on 
the 18FDG-PET scan. D: MRI of the thoracic spine in the 
region identified on the PET scan. E & F: Axial and sagital 
view of PET/CT scan of the patient showing that the lesion 
with 18FDG uptake was within the vertebral body. G: Endo-
scopic ultrasound image showing the tumour anterior to the 
vertebral body. H: Non-attenuated PET scan image from the 
PET/CT scan.
BMC Cancer 2007, 7:147 http://www.biomedcentral.com/1471-2407/7/147PET and CT scanning (as little as 0.5 cm in this case) was
sufficient for the lesion to appear to be in the vertebra
rather than just anterior to it.
In summary, although PET/CT scanning holds much
promise in the advancement of tumour localisation, our
case report demonstrates a potential danger in relying
solely on PET/CT scanning for the management of this
patient. This is further highlighted in a recent study which
showed that misalignment between CT and PET data can
occur from 2% to up to 50% of PET/CT scans [12,14].
While these issues are becoming well-recognised in radi-
ology, the potential for PET/CT to mislocalise lesions is
not well appreciated by clinicians requesting these scans.
We therefore suggest that in cases such as this, where there
is a discrepancy between in the PET and PET/CT, a dis-
claimer ought to be inserted in the PET/CT report to high-
light the potential misregistration which may occur.
Furthermore, what has not been addressed is the clinical
impact that these misregistrations may have. This report
underlines the importance of reviewing PET/CT images
and obtaining confirmatory/complementary anatomical
imaging of 18FDG-PET-defined lesions prior to embarking
on major surgery.
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